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Zusammenfassung 
Das kutane maligne Melanom ist ein Tumor mit steigender Inzidenz, der aus 
pigmentproduzierenden Melanozyten entsteht. Im Frühstadium der Erkrankung ist 
durch eine Operation eine vollständige Heilung möglich. Haben sich jedoch bereits 
Metastasen in anderen Organen gebildet, steht bisher keine kurative Therapie zur 
Verfügung. 
FGF/FGFR Signalsysteme spielen bei zahlreichen Tumorarten eine entscheidende 
Rolle im Zellwachstum und  -überleben und in der Angiogenese. Die Überexpression 
von Fibroblasten-Wachstumsfaktor 2 (FGF2) und Mutationen in Signaltransduktions  
wegen wie BRAF sind die charakteristischen Merkmale von Melanomzellen. 
Expressionsanalysen zeigten Überexpression von FGF5 in 90% der  untersuchten 
Melanomzelllinien, während FGF5 von gesunden Melanozyten praktisch nicht 
gebildet wird. 
 
Ziele: Die Ziele der Arbeit waren: A) Untersuchung der Auswirkungen von FGF5 
Überexpression und Inhibierung  auf den malignen Phänotyp von Melanomzellen in 
vitro. B) Analyse der Wirkung von FGF5  Überexpression auf das Tumorwachstum in 
vivo durch Xenotransplantationsexperimente in SCID-Mäusen. 
 
Methoden: Die Experimente umfassten: (I) Generation von isogenen Zellmodellen 
mit Überexpression von FGF5, (II) Analyse der Auswirkungen der FGF5 
Überexpression auf den malignen Phänotyp in vitro, (III) Analyse des Effekts der 
FGF5 Überexpression auf das Tumorwachstum in vivo, (IV) Etablierung von shRNA-
induziertem Knockdown des endogenen FGF5 mittels Lentiviren und Untersuchung 
der Auswirkungen des Knockdowns in vitro, (V) Analyse der Wirkung eines Extrakts 
der Heilpflanze Neurolena lobata auf Melanomzellwachstum und FGF/FGFR-
Expression. 
 
Resultate: Ergebnisse des Scratch Assay sowie des Invasion Assay zeigten 
deutlich den Einfluss der FGF5 Überexpression auf eine gesteigerte 
Migrationsfähigkeit der VM1 Zelllinie. Eine erhöhte Klonogenität wurde in VM1 Zellen 
mit FGF5 Überexpression im Vergleich zu GFP Kontrolle ebenfalls beobachtet. 
Keine signifikante Wirkung von FGF5 Überexpression wurde im Soft Agar Assay 
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beobachtet. Weiters wurde gezeigt, dass Überexpression von FGF5 keine 
Auswirkung auf die Proliferation von VM1 und VM21 Zellen in vitro  hat.  
Ergebnisse der Xenotransplantations Experimente in SCID-Mäusen haben gezeigt, 
dass Zellen mit FGF5 Überexpression früher Tumore bilden und eine Erhöhung der 
Tumorgröße im Vergleich zu Kontrollen aufweisen. Eine hohe Rate der 
Zellproliferation vor allem an den Tumorrändern wurde durch Ki-67 Färbungen 
nachgewiesen. Endothelzellen wurden durch Färbung mit vonWillebrand-Faktor 
identifiziert. In HE und Ki-67 Färbungen der Lunge und Leber von Mäusen wurden 
jedoch weder in der FGF5 überexprimierenden Gruppe noch in der Kontrollgruppe 
Metastasen aus den xenotransplantierten Tumoren beobachtet.  
Ein shRNA-vermittelten Knockdown des endogenen FGF5 zeigte eine hemmende 
Wirkung auf die Koloniebildung in vitro, hatte aber keine Auswirkung auf die 
Migrationsfähigkeit  der Zellen. 
Ergebnisse der Behandlung von Melanomzellen mit N. lobata Extrakt zeigten eine 
konzentrationsabhängige zytotoxische Wirkung in allen getesteten 
Melanomzelllinien. Eine Reduktion der Expression von FGF2 nicht jedoch von 
FGFR1 oder 4 wurde in den mit N. lobata Extrakt behandelten Zellen beobachtet. 
 
Schlussfolgerungen: Eine stimulierende Wirkung von FGF5 auf maligne  
Eigenschaften von Melanomzellen konnte sowohl in vitro als auch in vivo gezeigt 
werden. 
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Abstract 
Cutaneous malignant melanoma is a tumor derived from pigment producing 
melanocytes with rising incidence. Curative treatment of melanoma is possible only 
at an early stage, when complete surgical removal of the tumor is possible and once 
metastasis has occurred, no curative therapy exists. 
FGF/FGFR signaling systems play a critical role in tumor cell growth, survival and 
angiogenesis of several tumor types. Over-expression of fibroblast growth factor 2 
(FGF2) and mutations in signal transduction pathway molecules like BRAF are 
characteristic features of melanoma cells. 
 
Objectives: The purpose of the study was: A) Investigating the effects of FGF5 
over-expression and knock down on the malignant phenotype of melanoma cells in 
vitro.  B) Analyzing the effect of FGF5 over-expression on tumor growth in vivo by 
xenotransplantation experiments in SCID mice.  
 
Methods: The thesis included (I) Generation of isogenic cell models over-expressing 
FGF5, (II) Analysis of the Impact of FGF5 over-expression on the malignant 
phenotype of melanoma cells in vitro, (III) Analysis of FGF5 over-expression on 
tumor growth in vivo, (IV) Generation of lentiviral shRNA-mediated knock down of 
endogenous FGF5 and investigating the impact of down modulation of endogenous 
FGF5 in vitro, (V) Analysis of the effect of an extract  from the medicinal plant 
Neurolena lobata on melanoma cell growth and FGF/FGFR expression. 
 
Results: Results of the scratch assay as well as the invasion assay showed clearly 
the influence of FGF5 over-expression to result in a more migratory phenotype in the 
VM1 cell line. An increased clonogenicity was also observed in VM1 cells with FGF5 
over-expression compared to GFP controls. No significant impact on the ability of 
cells expressing FGF5 to form clones in soft agar was observed in contrast to cells 
with the GFP construct. Relating to effects of FGF5 over-expression on proliferation 
of VM1 and VM21 cells in vitro, no difference was observed compared to GFP over-
expressing cells.  
Results of xenotransplantation experiments in SCID mice showed that cells with 
FGF5 formed palpable tumors earlier and tumor volume was increased in contrast to 
mock transfected controls. A high rate of cell proliferation especially at the tumor 
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margins was demonstrated by Ki-67 staining. Endothelial cells were identified by 
staining for vonWillebrand factor. The occurrence of metastasis was observed 
neither in the FGF5 over-expressing nor in the control group when analyzed by HE 
and Ki-67 staining of lungs and livers of the mice. 
ShRNA-mediated knock down of endogenous FGF5 showed an inhibitory effect on 
colony formation in vitro, but had no effect on the migration ability of the cells.  
Treatment of melanoma cells with N. lobata extract led to dose-dependent 
cytotoxicity. A reduction in FGF2 expression was detected after treatment with        
N. lobata extract, while no difference in expression of FGFR1 and FGFR4 was 
observed. 
 
Conclusion: A stimulating effect of FGF5 on the malignant phenotype of melanoma 
cells could be demonstrated in vitro and in vivo. 
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1 Aim of the Study 
 
From previous data on FGF5 expression in melanoma and its role in astrocytic brain 
tumors it is hypothesized that over-expression of FGF5 contributes to melanoma 
growth and spreading by autocrine and paracrine activities facilitating angiogenesis 
and metastasis. Targeting FGF5-dependent signals may consequently offer novel 
therapeutic alternatives for combating melanoma. 
 
The aim of this thesis was therefore to investigate the impact of FGF5 on tumor 
progression of melanoma and evaluate its potential implications for prognosis and 
therapy. For that purpose I analyzed:  
 
 The effects of FGF5 over-expression and knock down on the malignant 
phenotype of melanoma cells in vitro with regard to proliferation, inhibition of 
cell death, migration, invasion and induction of angiogenesis.  
 
 The effect of FGF5 expression on tumor growth in vivo by a 
xenotransplantation experiment in SCID mice. 
 
 The impact of Neurolena lobata extract on FGF/FGFR expression in 
melanoma cells. 
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2 Introduction 
2.1 Cellular and molecular biology of melanoma 
Melanocytes are found in a wide variety of human tissues. They appear in the skin, 
but also in the eye, the meninges of the brain, in the heart and in bone.  The color of 
the eyes depends on the quantity, quality, and distribution of the pigment melanin, 
which occurs in two types: black to brown eumelanin and yellow to reddish 
pheomelanin [1]. In the skin melanocytes are located in the germinal layer of the  
epidermis and determine skin color (Figure1) [2, 3].  
Within the epidermis, melanocytes reside in the basal layer in a ratio of about 10 
keratinocytes to 1 melanocyte [4]. It has been estimated that each melanocyte is in 
contact with 40 nearby keratinocytes. Through a process called melanogenesis, 
melanocytes produce melanin and supply it via dendrites to surrounding 
keratinocytes. 
 
 
Figure 1: Location of melanocytes and keratinocytes in human skin [4]. 
 
UV is one of the major environmental factors, which causes an increase in melanin 
production. Melanin has a function as potent free radical scavenger in humans, 
protecting the DNA of skin cells from reactive oxygen species (ROS) that can be 
formed as a first consequence of UV exposure in high concentrations [5, 6].  
Under normal condition in the skin, there is a homeostatic balance between 
melanocytes and surrounding cells. Keratinocytes control melanocyte growth and 
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behaviour through a complex system of paracrine growth factors and cell–cell 
adhesion molecules. 
A change of epistasis is thought to be the entry point of melanoma development and 
is achieved by environmental, genetic as well as by epigenetic alterations in the skin 
tissue (Figure 2) [7]. 
 
 
Figure 2: Factors suggested to influence melanoma development [8]. 
2.2 Homeostatic imbalance and dysplastic nevi 
Alteration of homeostatic balance can lead to altered expression of cell–cell 
communication molecules and to development of melanoma. Melanocytes acquire 
the ability to express specific cell surface molecules allowing them to adhere to each 
other, survive, grow and migrate [2]. 
In the normal skin condition melanocytes and keratinocytes express E-cadherin, 
which mediates the communication and adhesion between melanocytes and 
keratinocytes [8, 9]. Disruption in E-cadherin and separation of melanocytes and 
keratinocytes appears to be one of the earliest steps in melanoma progression      
[10, 7]. On the other hand it is suggested that N-cadherin on melanoma cells is a 
major inductor for the formation of a dysplastic nevus and facilitates interaction with 
endothelial cells as well as fibroblasts. Beside N-cadherin, up-regulation of Mel-CAM 
receptor and zonula occludens protein-1 (ZO-1) are involved in melanoma-
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melanoma interactions and melanoma progression (Figure 3) [2]. During melanoma 
progression there is a cadherin subtype switch from E- to N-cadherine which creates 
a milieu favoring tumor formation and invasion.  
 
 
Figure 3:  Dynamics of intercellular interactions under normal and pathological situations during melanoma 
development. (a) Normal melanocytes reside close to the basement membrane and form an 'epidermal 
melanin unit' that contains one melanocyte and five to eight keratinocytes. Melanocytes interact with 
adjacent keratinocytes through E-cadherin, desmoglein 1, and connexins. This contact-dependent 
interaction is required for the growth and phenotypic control of melanocytes by keratinocytes. (b) Malignant 
melanoma cells proliferate, penetrate basement membrane, and invade into dermis. A shift of cadherin 
profile from E to N during melanoma development not only frees the cells from epidermal keratinocytes, but 
also confers new adhesive properties. Melanoma cells form N-cadherin-mediated adhesion and connexin-
mediated gap junctions with N-cadherin-expressing fibroblasts, endothelial cells, and adjacent melanoma 
cells. Mel-CAM and its unknown ligand are also involved in melanoma–melanoma cell interaction, which is 
implicated to play a role in the progression of melanoma [11]. 
2.3 Genetic aberrations and melanoma progression 
Senescence is the loss of the ability to proliferate after a finite number of divisions. 
Once the cells overcome this barrier of cell senescence, they become neoplastic, 
immortal and aggressive [12]. Concerning melanoma it is known that INK4A, CDK4 
and ARF are three melanoma susceptibility genes which are involved in the process 
of cellular senescence. The INK4a/ARF/INK4b locus (known as CDKN2a and 
CDKN2b) on chromosome 9p21 is deleted in many cancers including melanoma. 
This locus encodes three genes ARF (also known as p19ARF and p14ARF), 
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p15INK4b and p16INK4a. p15INK4b and p16INK4a  have a function as inhibitors of the 
cyclin-dependent kinases, CDK4 and CDK6, which promote proliferation. Mutations 
in p16INK4a gene were found in less than 25% of melanomas [13]. ARF as a tumor 
suppressor has the ability to bind and inactivate the MDM2 protein resulting in p53 
stabilization [14]. Mutations in the tumor suppressor gene p53 are very rare in 
melanoma, less than 5% despite extreme chemoresistance of melanoma. One 
explanation for this paradox is that p53 function could be disabled by lesions that 
disrupt other components of the pathway that may also contribute to compromise the 
apoptotic process [15]. Up-regulation of anti-apoptotic factors (members of the Bcl-2 
family) and down-modulation of pro-apoptotic genes (Apaf-1) are frequent in human 
melanoma [16]. For example, Apaf-1 (apoptotic protease activating factor-1) is a 
downstream effector of p53 which induces apoptosis in the presence of DNA 
damage. Down-regulation of this protein in cells reduced p53-dependent apoptosis 
and mediated oncogenic transformation. Decreased expression of Apaf-1 seen in 
correlation with melanoma progression could be interpreted as an event contributing 
to melanoma chemoresistance [15].  
Activating mutations in the oncogene B-RAF are found in up to 80% in benign naevi 
and almost 70% of  melanomas [17]. Mutations in B-Raf lead to downstream 
activation of the Mitogen Activated Protein Kinase/Extracellular Regulated Kinase 
(MAPK/ERK) pathway, which in turn down-regulates the proapoptotic proteins BIM 
and BAD leading to increased resistance to apoptosis. 
The presence of a c-kit-activating mutation in metastatic malignant melanoma 
suggests that a small number of melanomas may progress by a somatic mutation of 
the c-kit gene [18]. Somatic mutations in NRAS have been found in ~ 13-25% of all 
malignant melanomas [19, 20, 21]. 
Result of these mutations is constitutive activation of NRAS signaling pathways. 
NRAS mutations are found in all melanoma subtypes, but may be slightly more 
common in melanomas derived from chronic sun-damaged (CSD) skin [19, 21]. In 
the vast majority of cases, NRAS mutations are non-overlapping with other 
oncogenic mutations found in melanoma (i.e. B-RAF mutations, c-kit mutations, 
etc.). Akt/PKB is a core component of the PI3K signaling pathway. Several studies 
have shown that activation of the Akt/PKB pathway induced the transcription of a 
wide range of genes, especially those involved in cell proliferation, apoptosis and cell 
survival [22]. HGF/SF and IGF-I are two growth factors which are secreted by 
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melanoma cells and surrounding stroma contributing to activate Akt/PKB signaling   
in an autocrine and paracrine manner [23, 24] and leading to increased proliferation 
(Figure4). 
 
 
 
Figure 4: Melanoma signaling networks. Shown is a simplified diagram of three of the major genetic 
networks involved in melanoma tumorigenesis, survival, and senescence. Included in the NRAS 
signaling network (green) are the MAPK and the PI3 Kinase/AKT pathways, which have been implicated 
in melanoma proliferation, survival, and progression. The CDKN2A locus encodes two separate tumor 
suppressors, p16 and p14ARF, both of which are thought to contribute to senescence and tumor growth 
restriction. The p53/Bcl-2 signaling network (red) is a major contributor to melanoma apoptosis and 
chemosensitivity and is regulated by many of the oncogenic melanoma pathways.  At the top of the  
figure selected therapeutic agents that target each of these genetic networks are shown [25]. 
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2.4 Fibroblast growth factors (FGF) and FGF-receptors 
2.4.1 Evolution of the FGF and FGFR gene family 
Fibroblast growth factors (FGFs) make up a large family of polypeptide growth 
factors. The FGF Family comprises a signalling system that is conserved throughout 
metazoan evolution. During evolution, the FGF family expanded in two phases, 
during early metazoan evolution and during the evolution of early vertebrates. In the 
first phase, FGFs expanded from two or three to six genes by gene duplication, while 
in the second phase the expansion took place by two large genome duplications. In 
contrast, the FGFR family has expanded only in the second phase. However, the 
acquisition of alternative splicing by FGFR has increased their functional diversity. 
The mechanisms that regulate alternative splicing have been conserved during 
evolution [26, 27, 28]. 
In the mammalian FGF family, there are 22 genes encoding for FGFs. The human 
FGF gene family can be divided into seven subfamilies based on structural 
homologies and phylogeny: The intracellular subfamily = FGF11 subfamily: FGF (11-
14), the hormone-like subfamily: FGF19, FGF21 and FGF23 and the canonical 
subfamilies, which can be divided in to five groups: the FGF1 group (FGF1, FGF2), 
FGF4 group (FGF4-6), FGF7 group (FGF3, FGF7, FGF10, FGF22), FGF8 group 
(FGF8, FGF17, FGF18) and FGF9 group (FGF9, FGF16, FGF20) (Figure 5). 
Members of these subfamilies share a varying degree of sequence, biochemical and 
developmental similarities [26, 28, 29]. FGF-like peptides (11-14) do not activate the 
FGF-dependent signaling pathway and therefore are not considered to be members 
of the genuine FGF family although they share a high sequence identity with this 
family [30]. 
FGF receptors are a subfamily of receptor tyrosine kinases (RTK). Four genes 
encode the four known FGF receptors. Each of these genes is localized on different 
chromosome and alternative splicing causes functional diversity and specify of 
FGFRs (Figure 5) [31, 32, 33]. 
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Figure 5: Members of the human fibroblast growth factor (FGF) gene family [34]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            
Table 1:  FGF-Receptor genes, their chromosomal localizations, splice variants and ligand  
 Specifities  for FGF1-FGF10 are shown [34]. 
2.4.2 Structural and functional properties of FGFs and FGF-receptors 
Human FGF family members range in size from 17 kDa to 34 kDa and posses a 
homologous 120 amino-acid central core domain with twelve anti-parallel ß-strands in 
core domain [35, 36]. Most FGFs (3, 4, 5, 6, 7, 8, 10, 15, 17, 18, 19, 21, 22, 23) have 
classical amino terminal signal peptides that ensure the secretion through the 
endoplasmatic reticulum pathway. 
In contrast FGF 9, 16 and 20 are secreted in spite of their lack of a signal peptide, 
whereas, FGF1 and 2 seem to remain intracellular until they are released from 
FGFR1 8p12 
FGFR1b 
FGFR1c 
FGF1,2,3 and 10 
FGF1,2,4,5 and 6 
FGFR2 10q26.12 
FGFR2b 
FGFR2c 
FGF1,3,7 and 10 
FGF1,2,4,6 and 9 
FGFR3 4p 16.3 
FGFR3b 
FGFR3c 
FGF1 and 9 
FGF1,2,4,8 and 9 
 
FGFR4 5q35.2 FGFR4 FGF1,2,4,6,8 and 9 
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decaying cells. FGFs 11-14 also lack a signal sequence and are consider remaining 
intracellular and functioning within cells in a receptor independent manner [27,  29]. 
FGF signalling exerts a combination of biological and physiological effects (Table 2) 
that contribute to chemotaxis, cell growth, proliferation and differentiation and 
induced mitogenic and angiogenic activity in cells of mesodermal and 
neuroectodermal origin [37]. 
Specific members of the FGF family are key molecules during embryogenesis  
[38, 39].They also play a crucial roles in development and wound healing. Several 
FGFs play an essential role during gastrulating, the formation of all three germ layers 
and organogenesis especially in lung, limb and the nervous system [29, 40, 41, 42]. 
For instance, fibroblast growth factor 5 (FGF5) is widely expressed in embryonic but 
scarcely in adult tissues [43]. FGF5 was originally identified based on a screening 
approach for genes present in tumors that are able to transform NIH 3T3 cells [44]. 
The FGF5 protein is 267 amino acids long and possesses 40% and 50% homology 
in the core region to FGF1and 2 and is secreted as a glycoprotein [44, 45, 46].  
Human and murine FGF5 genes contain consensus sequences for secretion and 
their translation is stringently controlled by several upstream AUGs [46]. It is 
suggested that FGF5 plays a role in embryonic stem cell regulation especially for the 
neuroectoderm [47, 48]. FGF5 is expressed in neonatal brain, therefore it is tempting 
to suggest that FGF5 is a neurotrophic factor [49]. FGF5 plays a role in the 
peripheral nervous system as a muscle-derived trophic factor for motoneurons [50]. 
FGF5 negatively regulates a step of the hair follicle growth cycle. FGF5 knockout 
mice exhibit abnormally long hair in the absence of any other defect and loss-of-
function mutations in the FGF5 gene account for hereditary variations in hair length 
in canines and felines [30].  
The role of FGFs in organogenesis has been shown in mouse genetic models as 
well as human pathologies. Examples are FGF8 knockout mice that are defected in 
gastrulation and FGF9 and FGF10 knock mice which die at birth because they have 
not developed functional lungs [28]. FGFs can also stimulate wound healing 
angiogenese and tissue repair in adult organism. 
Regarding to wound healing, FGF1, FGF2 and epithelial specific FGFs 7 and 10 
stimulate proliferation and cell migration in the mesenchyme and the epithelium to 
achieve wound closure and re-epithelialization [52].  Endothelial cells express the 
IIIc-forms of FGFR2 and FGFR3 which make them responsive to FGFs that are 
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involved in wound healing responses [28]. It has been shown that FGF2 can 
stimulate the sprouting of new vessels in response to neovascularisation [28]. In 
addition to FGF2, some other FGFs are involved in angiogenese for example FGFs 
16 and 18 in cardiac tissue [52]. In some cells, FGF-induced activation of FGFRs 
leads to proliferation, migration and differentiation in other cell types  it contributes to 
cell cycle arrest, apoptosis or inhibition of differentiation [53]. 
 
Nr. 
Fibroblast growth 
factor (FGF) 
Phenotype of knockout mouse Physiological role 
1 FGF1 Normal Not established 
2 FGF2 
Loss of vascular tone slight losse  
of contex neurons 
Not established 
3 FGF3 Inner ear agenesis in humans Inner ear development 
4 FGF4 Ebryonic lethal 
Cardiac valve leaflet  
formation limb development  
5 FGF5 Abnormally long hair Hair growth cycle regulation 
6 FGF6 Defective muscle regeneration Myogenesis 
7 FGF7 
Matted hair  reduced nephron  
brancing in kidney 
Branching morphogenesis 
8 FGF8 Embryonic lethal 
Brain, eye, ear limb 
development 
9 FGF9 
Postantal death Gender reveresal 
 lung hypoplasia 
Gonadal development 
organogenesis 
10 FGF10 Failed limb and lung development Branching morphogenesis 
11 FGF16 Embryoniv lethal Heart development 
12 FGF17 Abnormal brain development 
Cerebral and Cereberall 
development,Bone  
development 
13 FGF18 Delayed long-bone ossification  
14 FGF19 Increased bile acid pool 
Bile acid homeostasis 
 Lypolisis Gall bladderfilling 
15 FGF20 No knochout model Neurotrophic factor 
16 FGF21 No knockout model 
Fasting response Glucose 
homeostasis lipolysis and 
lypogenesis 
17 FGF22 No knockout model Presynaptic neural organizer 
18 FGF23 
Hyperphosphataemia Hypogly- 
caemia immature sexual organs 
Phosphate homeostasis  
vitamin D homeostasis 
 
Table 2: The physiology of FGFs [55]. 
2.4.3 FGF-receptors (FGFRs) 
FGFRs belong to the class IV family of RTKs. Four different FGFRs are known. They 
possess similarities in their amino acid structure. The FGF receptors begin with an 
extracellular N-terminal signal peptide. The intracellulare region includes 
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characteristic sequence containing the amino acid cysteine in a specific spacing. 
These cysteines are stabilized by disulfide bridges, which build the structure of the 
three Immunoglobolin-like domains (lg I-III). In addition FGFRs contain a cluster of 
acidic amino acids between Ig I and Ig II forming a linker region called acidic box  
and a transmembrane domain followed by the tyrosine kinase domain in the 
intracellulare region, which is subdivided into TRK1 and TRK2 (Figure6). 
 
                              
Figure 6: Structure of FGF receptors [56]. 
 
The FGF signaling pathway induces a variety of different effects. In order to achieve 
this amount of diversity the signaling system requires a variation at the level of the 
receptor.Different forms of receptors are generated through different expression of 
FGFR genes and alternative splicing of the same gene [55]. The Ig III-like domains 
of FGFR 1-3 contribute to different splicing by creation of IIIb and IIIc variants of the 
respective receptors (Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7:  Overview of variants of FGF-seceptors generated by the mechanism of alternative splicing. 
Concerning the FGFR-2 gene, Ig domain IIIb is pre-dominantly expressed in the epithelial lineage, while Ig IIIc 
domains are only expressed in the mesenchymal lineage [55, 56, 57].  
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In general, the IIIb isoforms are expressed on epithelial cells, while the IIIc isoforms 
are often expressed on mesenchymal cells. 
It is suggested that changes in the IgIII domain influence ligand binding (Figure 8). In 
addition specific heparin-binding sites in IgII domains of FGFRs are required for a 
strong binding to heparansulfateproteoglycanes (HSPG). It was shown that the 
binding of fibroblast growth factors to these extracellular polysaccharides constitutes 
a mechanism limiting the diffusion radius of FGFs and sequestering them in the 
extracellular matrix of the connective tissue. FGFs can be released from such 
microenvironmental stores by proteolytic enzymes or by the action of a specific FGF-
binding protein (FGF-BP).  This protein is secreted into the extracellular space where 
it reduces affinity of the FGFs to heparin to make it available for signalling. This was 
shown for FGFs1 and 2 during wound healing [28]. 
 
                       
 
Figure 8: Protein structure of FGFRs. FGFRs is receptor tyrosine kinases consisting of cytoplasmic interrupted 
kinase domains and transmembrane domains with high degrees of homology between different FGFRs. The 
extracellular domains consist of three immunoglobulin (Ig)-like loops that bind FGFs between Ig-loop 2 and 3. 
FGFRs 1-3 are subject to alternative splicing events that affect Ig-loop 3 and therefore have large effects on the 
receptors ligand specificity. HSPGs mediate receptor-ligand binding [28].  
2.4.4 Dysregulation of FGF signaling in cancer 
The binding of FGFs to their receptors induces RTK dimerization, which undergo 
auto/trans-phosphorylation on tyrosine residues located within the carboxy terminal 
cytoplasmatic tail. These phosphorylatet residues serve as a docking site for 
downstream signaling proteins. 
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Two main pathways are involved in downstream signaling. Signaling through binding 
of FGF-receptor substrate FRS2α to the juxtamembrane region of the receptors via a 
Src-homology 2 (SH2) domain leads to activation of the ras-pathway and further 
downstream the PI3K/Akt-pathway and/or MAPK pathway. The second pathway 
recruits phospholipase Cγ to produce 1, 2-diglycerides to activate PKC that 
synergistically upregulates MAPK signaling [31, 58].  
Activation of various signal transduction cascades plays a significant role in 
pathogenesis of human cancers via stimulation of tumor growth/survival and 
neoangiogenese and tumor cell migration (Figure 9). 
 
 
Figure 9: Overview of oncogenic signal cascades activated by FGFs [59]. 
 
There are many possibilities that can cause to dysregulation of FGF signaling 
pathways. Over- expression of FGF ligands has been observed in a great variety of 
human tumors. Autocrine production of FGFs is a common hallmark of cancer and 
over-expression of secreted FGFs supports autocrine signaling loops. Up-regulation 
of FGF2 is found in breast and lung cancer. In addition over- expression of FGF3, 4 
and 8 which are normally not expressed to high levels in adult tissues has been 
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found in a number of human neoplasms, for instance in Kaposi´s sarcoma, and in 
carcinomas of the breast, prostate, ovary and esophagus [60-63]. Over-expression 
of FGF18 and FGF19, which act through the receptors FGFR3-IIIc and FGFR4 on 
the tumor cells, has been shown in colon cancer. 
Dysregulation of FGF signaling can also occur by alteration of FGFRs through 
activating mutations, amplifications and translocations of FGF receptor genes. 
Mutations in FGFR genes are found not only in the kinase domain but also over the 
complete length of the gene [28]. FGFR2 mutations are mainly observed in epithelial 
tumors, while FGFR3 mutations are common in multiple myeloma and autosomal 
mutations in FGFR4 are frequent in rhabdomyosarcoma [64, 65]. 
Concerning FGFR1 and FGFR2, deregulations are more commonly by gene 
amplification. FGFR1 amplification has been described for example in breast cancer, 
ovarian cancer, bladder cancer, oral squamous cell carcinoma and 
rhabdomyosarcoma. FGFR3 over-expression in multiple myeloma is achieved by 
translocations. These translocations are involved in conversion to full multiple 
myeloma [66].  
Regarding tumor cell migration, there are many studies, which suggest that FGFs 
stimulated the tumor cell migration and may be a drivers of metastasis. In many 
tumor types FGFs induced activation of alternative survival pathways and provide a 
strong growth advantage for the tumor through autocrine FGFs and/or constitutively 
activated receptors [28]. In addition to autocrine stimulation, FGFs 1, 2, 4, 5, 8 and 
18 have paracrine effects on vascular endothelial cells through FGFRs 1 and 2 and 
induced endothelial cell proliferation and secretion of essential factor for 
angiogenese like metalloproteases and plasminogen [67]. 
It is suggested that FGF5 may participate in autocrine and paracrine pathways 
promoting pancreatic cancer cell growth in vivo [68] and FGF5 was identified as an 
overexpressed antigen in multiple human adenocarcinomas [69]. The predominant 
FGF5-binding FGFR1 variant IIIc [70] was found to be up-regulated in various 
cancer types [71], thus generating the conditions for autocrine loops.  
In astrocytic brain tumours oncogenic activities of FGF5 on growth- survival- and 
migration of tumor cells was shown [43]. In melanoma, an oncogenic role of basic 
FGF (FGF2) has been identified as an important hallmark of melanoma cells in 
contrast to normal melanocytes [72]. Compared to FGFR2 and 3, FGFR1 and 
FGFR4 are highly expressed in nearly all melanoma cell lines. Reports have 
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established a correlation between FGFR4 protein expression and survival of 
melanoma patients. In addition to FGF2, expression of FGF5 is also found in 
melanoma. Our previous data showed very low expression of FGF5 in melanocytes 
but over-expression of FGF5 in the majority of the tested melanoma cell lines [73]. 
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3 Materials and Methods                                           
3.1 Cell lines and media 
The institute of Cancer Research supplied all melanoma cell lines (Table3), which 
have been described previously [74]. We used Roswell Park Memorial Institute 
(RPMI) medium with 10% fetal bovine serum (FBS) for all cell lines. RPMI medium is 
a hydrogen-carbonate buffer system in a solution of glucose, salts, amino acids and 
vitamins, which was purchased from Sigma Aldrich and uses phenol-red for 
indicating the pH-value. FBS (Sigma Aldrich) is used to supply cells with a variety of 
growth factors, hormones and trace elements to make cell survival in culture 
possible. Penicillin/streptomycin solution was added to the medium only during 
selection of stable transfectants, was bought from PAA and used at an end-
concentration of 1%. 
 
  
 
 
 
 
 
 
 
 
 
 
 
Table 3: Used cell lines, including VM (Vienna Melanoma) numbers, origin and histology. 
Establishment of cell lines from primary tumours (PT), lymph node (LN) or brain (BR)  
metastases of malignant melanoma is also indicated. 
3.2 Standard growth conditions 
All melanoma cell lines were kept in a humidified incubator (Forma Scientific) at 
37°C and 5% CO2. Tissue culture flasks (T25 (=25cm2), T75 (=75cm2) and T175 
(=175cm2)) were bought from Greiner Bio-One or from BD Falcon. 6-/12- and 24-well 
plates were bought from IWAKI, 96 well-plates from TPP. Medium with10% FBS was 
always used for cells except where indicated otherwise.  
3.3 Splitting 
The medium was aspirated and cells were washed once with PBS (2.7 mM EDTA 
(Merck), 137 mM NaCl (Merck) and10 mM Na2HPO4 (Merck), pH 7.4) Trypsin/EDTA 
(T/E, 0.01% EDTA (Fluka), 0.1% Trypsin (Difco)) was added onto the cell layer and 
incubated about 5 minutes at 37°C. Detachement was monitored using the 
Cell line Origin Histology 
VM-1 FTSL-A LN SMM 
VM-21 RHTP PT NM 
VM-7 GTBS PT NM 
VM-8 GUBSA LN NM 
VM-24 SHTJ LN Unknown 
VM-48 KAKA BR NM 
VM-47  HOST BR NM 
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microscope. Cells were resuspended in medium and the desired number of cells 
was transferred into a new flask, containing fresh medium. 
3.4 Cell counting 
For cell counting, either a Casy Cell Counter (Schärfe) or a Neubauer Chamber 
were used [75].  
3.5 Freezing 
After culturing the cells to about 80% confluence, cells were trypsinized and 
resuspended in 5 ml medium and transferred to 15 ml Falcon tubes, pelleted at 600-
800 rpm for 5 min.and supernant was discarded. Cells were resuspended in 2 ml 
medium. If cells were on selection (for stable transfectants), the medium also 
contained the corresponding selection reagent as well as penicillin and streptomycin. 
DMSO (dimethyl sulfoxid) was added to a final concentration of 50 μg/ml and 1ml of 
cell suspension was transferred into cryotubes (Greiner). The suspension was put on 
ice and cooled down in a styrofoam container at –80°C for at least 24 hours, but not 
longer than 72 hours. Afterwards, cells were transferred into a liquid nitrogen tank for 
long term storage. 
3.6 Isolation of RNA 
Medium was discarded, Trizol (Invitrogen) was added onto the cell layer and cells 
were incubated in Trizol solution for about 5 minutes. Lysates were transferred into 2 
ml Eppendorf tubes. Chloroform (0.2 x vol. Trizol) was added, the tubes were 
vortexed and centrifuged at 12000 g for 15 min at 4°C. Aqueous supernatant, 
containing solubilzed RNA, was transferred into new Eppendorf tubes and 
isopropanol (0.5 times vol. Trizol) was added and tubes were incubated for 10 min. 
and centrifuged again at 13000 g at 4°C for 11 min. Supernatant was discarded and 
75% EtOH/DEPC (diethylpyrocarbonate-treated) was added onto the pellet and 
centrifuged at 13000 g at 4°C for 10 min. The alcohol was discarded and the pellet 
was air dried and resuspended in 15 μl DEPC water. Isolated RNA was stored at -
20°C for shorter or at –80°C for longer periods of time. 
3.7 Determination of RNA concentration 
Determination of RNA concentration was achieved by OD260 measurement on a 
NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific).  
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3.8 Synthesis of cDNA 
2 μg RNA were diluted with DEPC water to 13 μl and incubated for denaturation at 
70°C for 10min. Tubes were put on ice and 7 μl cDNA Synthesis Master Mix (MM) 
were added to a total volume of 20 μl. The reaction was incubated for 1.5 hours at 
37°C. The quality of cDNA was tested by performing standard RT-PCR of a 
“housekeeping gene” followed by agarose gel electrophoresis. cDNA was stored at –
20°C.                  
                                                   Solution (Concentration)             Volume (μl)  
       cDNA Synthesis Master Mix (1 x)        
 
 
                                
 
                                                                                                                      7 μl total volume                                                  
3.9 TaqMan - “Real Time” quantitative RT-PCR (qRT-PCR) 
TaqMan Master Mix was prepared on ice and 2 μl cDNA were added into two wells 
(per sample) of an Optical 96-Well Reaction Plate (Micro AmpR; Applied 
Biosystems). Master Mix was added to a total volume of 12 μl and mixed. PCR was 
started and fluorescence measurement occurred after each cycle using an ABI 
Prism 7000 SDS thermocycler (ABI), according to ABI manuals. Taqman probes 
which were used in this thesis are listed below. 
                                                                                                      
 
                                                                         Solution (Concentration)                 Volume (μl) 
 
TaqMan qRT-PCR Master Mix (1 x)        
 
                                                                                 cDNA                                         2                                                                                                                 
                                                                                                                                                   23     total volum   
                      
 Taqman-Probes used for FGF5             
          
         HS 00170454m L 
 
             Lot :657375 
 
 
                  
House-keeping gene 
 
M-MLV RT buffer (5 x; Promega)       4     
Hexanucleotides (20 ng/μl)          0.5        
dNTPs (10 mM)                                   1 
DTT (100 mM)                                     1 
MMLV-RT (200 u/μl; Promega)         0.5 
 
TaqMan Probes (Applied Biosystems)         1.25 
           
TaqMan Master Mix (Applied Biosystems)   12.5 
 
                water bidest.                                   9.25 
 
      Beta 2-microglobulin  
             (B2M) 
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3.10 Gel electrophoresis (Nucleic acids) 
Agarose gels consisting of 1% (w/v) agarose (Biozyme) in 0.5 x TBE buffer (5.4 g/L 
Tris (Fluka) 2.75 g/L boric acid (Sigma), 1 mM EDTA), were used for size separation 
of DNA fragments of 1-3 kilobases (kb). 6 x loading buffer (333 μL/mL 6 x loading 
dye (Fermentas), 250 μL/mL 80% glycerol (Merck), 66.5 μL/mL 0.5 M EDTA, 0.5 
μL/mL 10 000 x Vistra-Green (GE Healthcare) was added to samples and loaded on 
to the gel. 2 μL Gene Ruler 1 kb DNA Ladder (Fermentas) mixed with appropriate 
amounts of water and loading buffer were used as a marker. Gel was run at a 
voltage of 50 V for 10 min, followed by 90 V for 30 min (power supply: Bio-Rad), in 
0.5 x TBE as a running buffer. 2% gels (marker: GeneRuler 100 bp Plus DNA ladder 
(Fermentas)) were used for smaller fragments and 0.5% gels for larger fragments. 
Bands were visualized using a FluorImager 595 Scanner from Molecular Dynamics. 
3.11 Isolation of proteins 
Lysis buffer II (LBII) was used for isolation of all non-secreted proteins for Western-
blot and SDS-PAGE analysis. Cells were trypsinized and washed with cold PBS. 
Centrifugation was done at 800 rpm for 5 minutes. All successive steps were done 
on ice. LBII was added onto the cell pellet. Volume of lysis buffer depended on cell 
amount and usually ranged between 30 μl for around 500 000 cells and 120 μl for 2 
million. The pellet was resuspended by pipetting up and down for several times, then 
the Insoluble components were removed by centrifugation at 4°C and 20 800 g for 
10 minutes. Aqueous supernatant was transferred and stored at -20°C, for longer 
periods at -80°C. 
3.12 Determination of protein concentration 
The protein concentration of samples was determined by the Bradford Protein Assay 
(1:5 dilution in dH2O, Biorad) in duplicates. Samples, as well as BSA bovine serum 
albumin as standard protein for the calibration curve (Table 4 and Figure 10) were 
placed into PS microplate 96-well (Greiner). 190 μl of diluted Bradford solution was 
added and mixed, then incubated for about 10 minutes at RT. Absorbance was 
measured at 562 nm by using a SynergyHT plate reader (BioTEK) and Gen5 
software (BioTEK). From the calibration curve the concentration of samples was 
calculated. Obtained concentrations had to be multiplied by 10, because of the 1:10 
dilution of the samples. 
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                              Water (µl)           Lysis-Buffer (µl )       BSA  (1 µg / µl )      Conc.( µg / µl  )        Sample (µl )     
 
            blank 9 1 0 0  
 1 8 1 1 0,1  
 2 7 1 2 0,2  
 3 5 1 4 0,4  
 4 3 1 6 0,6  
 1 1 8 0,8  
 0  9 0,9  
 9    1 
 
Table 4: Pipetting Scheme of BSA standards and protein samples. All concentrations were  
calculated by taking the average of double determinations. 
 
                                   
Figure 10: Example of calibration curve used for determination of protein concentration by 
Bradford Assay. 
3.13 SDS-polyacrylamid gel electrophoresis 
For detection of a protein of interest in cell lysate or supernatant, samples were 
subjected to SDS-PAGE [76] and Western blot [77]. The Mini Protean 3 system (Bio-
Rad) was used for gel electrophoresis and transfer of protein to a PVDF membrane 
(Hypond-P, GE Healthcare) for immunodetection. Separating and stacking gel were 
prepared as described in (Table 5) with densities between 7.5 and 15% according to 
protein sizes desired to be investigated. The separation gel was cast and topped 
with isopropanol. After polymerization, the isopropanol layer was rinsed off with filter 
paper (Schleicher and Schuell). Afterwards, the stacking gel was cast on top and 
sealed with a ridge. Following polymerization, the ridge was removed and pockets 
were cleaned with SDS Running Buffer (25 mM Tris, 192 mM glycin and 0.1% SDS), 
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which was also used as running buffer for SDS-PAGE. 40 μg proteins of samples 
were prepared using 5 x Laemmli loading buffer. Samples were heated for 5 minutes 
at 95°C to denature proteins and loaded onto the polyacrylamide gel. The 
PageRuler™ Prestained Protein Ladder (Fermentas) was used to determine the 
molecular weight of the proteins loaded. Protein samples were assimilated at 50 V in 
the stacking gel and separated at 120 V in the separating gel. 
                                                                                                                                     
Separation Gels 10% Volume 
Water 1.960 ml 
1.6 M Tris pH 8.8 1.250 ml 
20% SDS 50 μl 
30% Acrylamid/Bis;    
29:1(Bio-Rad) 1.675 ml 
10% APS (Merck) 25 μl 
TEMED (Amresco) 5 μl 
 
Table 5: Recipes for PAGE gels                                                                                                                                                          
3.14 Western blot 
The Western blot is a standard method for detection of specific proteins. After 
protein separation via SDS-PAGE, Proteins were transferred to a polyvinylidene 
fluoride (PVDF) membrane. The Mini Protean 3 system was used for blotting. 
Sandwiches of buffer soaked sponges and filter papers were prepared carrying the 
positively charged membrane (activated with methanol) and the gel. The blotting 
sandwich was assembled, and transfer was performed at a voltage of 18 V, 
overnight in the fridge (4°C). After protein transfer, the membrane was dried and 
reactivated with methanol. Quality of transfer was controlled by staining protein 
bands with Ponceau S Solution (0.5 g/l Ponceau S (Sigma) and 1 ml/l glacial acetic 
acid [79]. Membrane was incubated in the staining solution for about 5-20 minutes. 
The background was removed by washing with distilled water on the shaker. To 
increase quality, water was changed several times. Afterwards, the staining was 
documented using a photocopier. After reactivating with methanol and washing with 
PBST or TBST, the membrane was blocked for 1 hour with 5% Skim Milk Powder 
(Fluka) at RT on the shaker. Blocking solution was washed off 3 x 10 minutes with 
TBST. Incubation with primary antibodies (Table 6) occurred over night at 4°C on a 
rotator in a 4°C room. Next day, after 3 washing steps of 15 minutes each with 
PBST/TBST, the membrane was incubated for 1 hour with secondary antibodies. 
Stacking Gel 4% Volume 
Water 1.5 ml 
1.6 M Tris pH 8.8 0.625 ml 
20% SDS 12 μl 
30% Acrylamid/Bis;    
29:1(Bio-Rad) 
0.325 ml 
10% APS (Merck) 25 μl 
TEMED (Amresco) 2.5 μl 
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PVDF membrane was washed again, 3 x with TBST and 2 x with TBS, then 
incubated upside down on a parafilm with Immune-Star WesternC reagent (Bio-Rad) 
and visualized using Hyperfilm ECL (GE Healthcare). 
 
 
 
 
 
 
 
 
 
 
Table 6: List of antibodies used for immunodetection. Concentration of BSA as diluent was 3%, but 
 for milk powder (M) was 5%. 
3.15 Lipofection 
3 x 105 cells were seeded with 2 ml 10% RPMI medium into 6-well plates and 
incubated overnight. Next day, cells were adherent and around 50-80% confluent. 
FuGENE 6 (from Roche) was used as lipofection reagent. 3 μl transfection reagent 
were added to 97 μl serum-free medium (SFM; RPMI without FBS) mixed and 
incubated 5 minutes. 1 μg plasmid was added and incubated for another 25 minutes. 
Transfection suspension was added dropwise onto the medium-containing dishes 
with the cells and gently mixed. The following day, a change of medium was 
performed. 
3.16 Selection of stable transfectants 
In order to select for cells which have integrated the plasmids coding for FGF5 or 
short hairpin (sh)RNAs and a selection marker into their genome, the antibiotics 
neomycin / G418 and puromycin were used (Figure 11, Table 7). 
 
 
 
Primary 
Antibodies Dilution      Supplier Dilution   Size of Target 
FGF5 poly 
clonale  goat                                     1:1000 Santa Cruz sc124  BSA     30 KDA 
Secondary 
Antibody 
Dilution     supplier Dilution Size of Target 
Anti goat -    
HRP 
1:10 000       Dako    M       n/a 
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Figure 11:  PIRESFGFSEGFPlig vector containing the FGF5 cDNA. 
 
 
To reduce the risk of fake clone formation, a plasmid encoding for a bicistronic 
mRNA containing the gene of interest and GFP, separated by an internal ribosome 
entry site IRES [78] was used. Western blot analysis and qRT-PCR were performed 
to assess the expression of FGF5. 
To ensure good growth conditions, the selective medium was changed every two to 
three days. Usually after 1-2 weeks small, G418-resistant, GFP-fluorescing clones 
appeared. They were left to grow fully confluent for further sorting with FACS for 
GFP-positive cells. 
 
                                 
 
  
    
Table 7: End-concentration of additives during selection and cultivation 
 
3.17 FACS sorting of GFP-positive stable clones 
The day before sorting, 5 l filter-sterilized 1 x PBS, 2 l filter-sterilized 70% ethanol 
and 2 l filter-sterilized distilled water were prepared. 50 ml Falcon tubes containing 
35 ml growth medium containing 10% FBS were incubated over night at 4°C. Before 
sorting, the cells were trypsinized, pelleted and washed one time with PBS. 
Afterwards the pellet was resuspended in 1ml serum-free medium containing 
Cell line G418 PAA (μg/ml) 
VM 1 200 
VM 21 150 
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penicillin/streptomycin. The growth medium in the 50 ml Falcon tube was removed 
and instead 5 ml medium containing penicillin/streptomycin were added in each of 
the prepared tubes. As negative controls untransfected cells were prepared. FACS 
tubes containing the cells and Falcon tubes containing the growth medium were 
stored on ice and FACS analysis was performed. An appropriate number of GFP-
positive cells were sorted and centrifuged at 800 rpm (Beckman CS-6KR Centrifuge) 
for 5 min. The hardly observable pellet was resuspended in growth medium 
containing penicillin/streptomycin and G418 and transferred to a fresh culture dish. 
3.18 Lentiviral transduction 
1.6 x 104 cells (GUBSA, GTBS and HOST) were seeded in a 96 –well plate and 
incubated overnight. Next day medium was replaced with 110 μl fresh medium 
containing hexadimethrine bromide (final concentration 8 μg /ml) and 5 μl of lentiviral 
particles were added per well. Five different lentiviral particles each expressing a 
shRNA for silencing of FGF5 and a scrambled shRNA as control were used. After 24 
h the medium containing the lentiviral particles was removed from the wells, and 120 
μl fresh medium were added to each well. Next day the medium was changed again 
to fresh medium containing the appropriate amount of puromycin (0.6 µg/ml for VM 7 
and VM 8 cells and 0.8 µg/ml for VM 47 cells). Selective medium was changed every 
3-4 days until no more cells died. Then cells were expanded to assay them for 
knock-down of FGF5. 
 
                       
Used Lentiviral particles 
 
 
 
 
 
 
3.19 Cell viability assay (MTT assay) 
The MTT assay is a colorimetric assay that utilizes MTT (3-[4, 5-dimethylthiazol-2-
yl]-2.5- biphenyl tetrazolium bromide) to assess cell viability. MTT is a water-soluble 
yellow dye that is readily taken up by viable cells. Cell lines (10³ cells per 96-well) 
were seeded in 100 µl medium with 10% FBS and after 24 h inhibitory or stimulatory 
 
NM-004464 TRCN0000058878   1.9 × 10
7 
TU 
 TRCN0000058879 1.8 ×  10
7 
 TU 
TRCN000005880 2.1 × 10
7
 TU 
TRCN000005881 2.2 × 10
7 
TU 
TRCN000005882 1.9 × 10
7
  TU 
Scrambled 
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molecules were added as 2 x concentrations in 100 μl serum-free medium, resulting 
in a total volume of 200 μl (5% FBS). 5 days after treatment, cells were incubated for 
1-2 hrs at 37°C with the EZ4U reagent (Biomedica) according to the manufacturer’s 
instructions. To measure the cell viability, absorbance was measured at 450 nm, 
with 620 nm as reference wavelength. 
3.20  Clonogenic assay 
To test the capability of adherent cells to survive and to form colonies, cells were 
seeded in 6-well plates at very low densities (3000-5000) with 2 ml RPMI medium 
(10%). After about 7 days to two weeks colonies had formed, depending on the 
specific clonogenicity of the cell line used and these were stained with crystal violet.                        
3.21 Crystal violet staining 
Supernatant was discarded; cells were washed in PBS and fixed by incubation in 
methanol:acetone (1:1) for about 20 minutes. Then cells were exposed to crystal 
violet solution (0.1g/ml crystal violet in absolute ethanol) diluted 1:1000 in PBS and 
incubated for another 20 minutes. Staining solution was discarded and dishes 
washed with aqua dest. Cells were air dried over night. 
3.22 Growth curve 
Melanoma cells were seeded in 6-well plates at a density of 1 x 105 cells per well in 
medium with 10% FBS .Cell number was determined every two days till day 8 with a 
Casy cell counter (Roche Innovatis AG, Bielefeld, Germany). 
3.23 Invasion assay 
To test the movement and invasion of cells, 12 well-plate formats were used. Porous 
membranes of transwell chambers were coated with 28 μl collagen and placed into 
the wells and incubated overnight at 4°C. 800 μl RPMI medium with 20% FBS were 
added into the well and 40000 cells in 200 μl 10% RPMI medium were seeded into 
the upper chamber resulting in a total volume of 1 ml. Migration through the 
membrane pores was visualized by crystal violet staining. Incubation time was 72 
hours. 
3.24 Soft agar assay 
Preparation of soft agar medium and 1% agar solution was done the day before as 
follows: For preparation of soft agar medium, 2ml NaHCO3 (110 mg/ml, in water 
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bidest.), 1 ml glutamine, 17 ml water (bidest.) and 50 μl folic acid were added to 10 
ml (10 x) RPMI medium (Sigma). The solution was brought to a pH value of 8 and 
filter-sterilized. Then, 20 ml FBS and 1ml penicillin-streptomycin were added under 
sterile conditions. Considering the 1% agar solution, 1.2 g agar was added to 80 ml 
water (bidest.) and solubilised by boiling. Simultaneously another 30 ml of water 
(bidest.) were heated up and used to fill up the 80 ml suspension to 100 ml. At the 
end the suspension was boiled again. Afterwards, the solution was brought to a 
temperature of about 40°C for subsequent generation of the soft agar bottom. Soft 
agar medium and 1% agar solution were mixed 1:1. 1.5 ml was subsequently 
pipetted into each well of a six well plate, constituting the soft agar bottom. Air 
bubbles were prevented by leaving a low amount of solution in the pipette. 
Afterwards, plates were put in the fridge until the agar became solid, and then were 
put into the incubator over night. 
Cells were trypsinized and the appropriate number of cells (10000) was centrifuged 
(800 rpm for 5 minutes) and the pellet was resuspended in750 μl soft agar medium 
with a temperature of 37°C. 750 μl 1% agar solution (40- 41°C) were added to the 
cell suspension and mixed. A total volume of 1.5 ml was added on top of solid soft 
agar and resulted in a total volume of 3 ml (0.5% solid soft agar medium) per well of 
a six well plate. Solutions were kept on temperature in the water bath. To reduce 
velocity of temperature reduction, solutions were put into a tray containing warm 
water during pipetting. After the desired clone size was reached (>20 μm VM21, >15 
μm VM 1), the number of clones above threshold level was determined under the 
microscope.  
3.25 Hen´s egg test – chorionallantoic membrane (HET-CAM) assay 
Preparation of eggs at breeding day 6: The eggs were disinfected by biotensid, the 
egg shell was opened with an electric drill. By drilling, the egg shell was removed 
taking care not to drill directly into the egg white to avoid contamination. 3 ml of 
albumin was extracted using a syringe with an 18 gauge needle.The hole was 
sealed with autoclaved aluminum foil and the eggs incubated further (37 ° C, 5% 
CO2, 95% humidity). A filter paper was dipped into ether and put on the CAM. 
Subsequently, a sterile silicone ring with an internal diameter of 5 mm was placed on 
the sample area. Preparation of Cells: Melanoma cells with over-expression of FGF5 
and mock controls were seeded into 75-cm2 flasks and cultured to 70% confluence. 
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Then cells were trypsinized and 2 x 106 cells were counted and pipetted into 
Eppendorf tubes and centrifuged at 1200 rpm for 3 min. The supernatant was 
removed leaving only about 30 μl. The cells were resuspended and applied to the 
surface of the CAM on the prepared sample area and incubated till breeding day 11. 
The growth of the cells and the changes in the CAM were observed daily by a stereo 
microscope and photographed using a camera. 
3.26 Tumor growth in SCID mice 
Cell lines were seeded in 10% RPMI and incubated over night. 1 x 106 cells per 
mouse in 50 μl serum-free medium were injected subcutaneously into the flanks of 
SCID mice.Tumor formation was measured periodically by palpation, and the tumor 
size was determined using a Vernier calipe. Mice were sacrificed 40 days post 
injection. All experiments were carried out according to the Austrian and FELASA 
guidelines for animal care and protection. Tumors and organs were excised and 
tumor was divided into several parts. One part was immediately frozen in liquid 
nitrogen for extraction of RNA and protein and the second part was formalin fixed for 
paraffin embedding and histology.  
3.27 Hematoxylin and eosin staining 
Hematoxylin and eosin (H&E) stains are widely used for recognizing various tissue 
types and the morphologic changes that form the basis of contemporary cancer 
diagnosis. Hematoxylin has a deep blue-purple color and stains nucleic acids. Eosin 
is pink and stains proteins nonspecifically. In a typical tissue, nuclei are stained blue, 
whereas the cytoplasm and extracellular matrix have varying degrees of pink 
staining. Nuclei show varying cell-type- and cancer-type-specific patterns of 
condensation of heterochromatin (hematoxylin staining) that are diagnostically very 
important. Nucleoli stain with eosin. If abundant polyribosomes are present, the 
cytoplasm will have a distinct blue cast [79]. Paraffin embedded samples were 
deparaffinized in xylol and dehydrated in increasing percentages of ETOH. Slides 
were stained in hematoxylin (6 min) and counterstained in eosin (1min) following 
standards protocols. 
3.28 Ki-67 immunohistochemistry 
Determination of cell proliferation in tissue sections is often performed by detection 
of Ki-67 antigen. The polyclonal antibody (NCL-Ki67p) labels human Ki-67 antigen 
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during late G1, S, G2 and M stages of the cell cycle. Reagents: xylol, ethanol, PBS, 
citrate buffer, Tweeen 20 (for synthesis, Merck Best.Nr 8.22184.0500),ultra vision lp 
large volume detection system HRP polymer, normal goat serum and liquid DAB+ 
substrate chromogen system as well as hematoxylin, n-butylacetat, Entellan, Ki-67 
(MIB-1) mouse monoclonale antibody at a 1:100 dilution (Dako) was used for  the 
identification of murine Ki-67 antigen. All steps were performed following standard 
protocols. 
3.29 Von Willebrand Factor (vWF) antibody staining 
Von Willebrand Factor (vWF) is a large glycoprotein with a multimeric structure and 
a molecular mass ranging from 500 kDa up to more than 10,000 kDa. Expression of 
the von Willebrand Factor gene is tissue specific and confined to endothelial cells. 
Primary Antibody: Von Willebrand Factor, anti-human, rabbit polyclonal antibody at a 
1:1000 dilution (Dako). All steps were performed following standard protocols. 
3.30 Statistical analysis 
Statistical analyses were performed with Graphpad Prism software. Student´s t test 
was used for comparison of two groups and differences with p values < 0.05 were 
considered statistically significant. 
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4 Results  
4.1 Expression analysis of fibroblast growth factor 5  
Quantitative expression analysis of FGF5 (qRT-PCR) was performed in melanoma cell 
lines and primary melanocytes were included for comparison (Figure 12). 
 
 
 
           
 
 
     
 
 
 
 
 
 
 
 
  
Figure 12: Quantitative expression analysis (qRT-PCR) of FGF5 in a panel of human melanoma cell lines (VM) 
compared to primary human melanocytes (PM). Strong over-expression (10-9000 fold) of FGF5 was seen in 9 of 
17 melanoma cell lines [73].  
  
Quantitative expression analysis revealed that FGF-5 was up-regulated in the 
majority of the tested melanoma cell lines. 
4.2 Generation of isogenic cell models 
Two melanoma cell lines VM1 (FTSL-A) and VM21 (RHTP) with low endogenous 
FGF5 expression were stably transfected with a vector expressing human FGF5 and 
green fluorescent protein (GFP) from a bicistronic mRNA as well as a G418 
resistance marker. Cells were double selected for G418 resistance and GFP 
expression and the resulting cell pools were analyzed for FGF5 over-expression on 
mRNA and protein levels by qRT-PCR and Western blotting (Figure 13, 14). Mock 
transfected controls expressed only GFP and the antibiotic resistance marker. 
Transfectants achieved around 800-fold (VM1) and 600-fold (VM21) expression 
levels of FGF5 when compared to mock transfected controls. These high FGF5 
expression levels correspond to those observed in melanoma cell lines with high 
endogenous FGF5 expression (Figure13). Western blot analysis of media 
supernatants from stable transfectants confirmed secretion of high amounts of FGF5 
(Figure 14). 
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Figure 13: Quantitative expression analysis of FGF5 mRNA in VM1 and VM 21 cell lines, taking the 
 respective GFP control as reference. 
 
 
 
                                        
Figure 14: FGF5 protein expression was examined by western blot in the FGF5-transfected VM1 and VM21 cell 
line and GFP control cells. Specific FGF5 bands were detected at 30 kDa whereas ß-actin bands were detected 
at 42 kDa. 
4.3 Impact of FGF5 on the malignant phenotype of VM1 and VM21 in vitro 
Cells with over-expressed FGF5 were compared to respective mock transfectants by 
subjecting them to different in vitro assays.                                 
4.3.1 MTT assay 
To check, whether FGF5 over-expression has any effect on cell viability, cell lines 
(VM1, VM21) were seeded in RPMI medium with 0.1% FBS or 10% FBS and grown 
for 5 days and the viability of cells was measured by MTT assay (Figure 15). 
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Figure 15: Viability of melanoma cell lines VM1 and VM21 with FGF5 over-expression incubated in RPMI 
medium with 0.1 or 10% FBS for 5 days. The GFP control was taken as reference. *p < 0.05, **p < 0.01. 
 
The viability of cells with FGF5 over-expression was decreased in RPMI medium 
with 0.1% FBS.  In medium with 10% FBS there was either no difference (VM21) or 
a slight increase (VM1) in viability in the FGF5 overexpressing cells.  
4.3.2 Growth curves 
In a growth curve experiment, the effects of stable over- expression of FGF5, on the 
proliferation of melanoma cells were determined. Every two days cell number was 
measured by a Casy cell counter (Figure 16). 
 
Figure 16: Proliferation of melanoma cell lines (VM1, VM21 expressing FGF5 determined by the Casy  
cell counter. 10 000 cells per 6-well were seeded.  
 
Results showed no difference in proliferation of cells with FGF5 over-expression in 
contrast to GFP cells. Thus, FGF5 over-expression did not stimulate melanoma cell 
proliferation in vitro. 
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4.3.3 Clonogenic assay 
Melanoma cells with over-expressed FGF5 were then tested for their ability to 
survive and form clones, when seeded at very low density. After desired clone sizes 
were reached, depending on the specific clonogenicity of the cell line, cells were 
fixed and stained with crystal violet (Figure 17). 
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Figure 17:   Examples of clonogenic assays of transfected VM1 and VM21 cell lines. Cells were 
 seeded at low densities (5000 cells/6-well). 
  
After staining the colonies with crystal violet, the dye was dissolved with 10% SDS 
solution and photometric measurement of the crystal violet absorption was 
performed. The amount of crystal violet which was taken up by the cells serves as a 
readout for the number of cells (Figure 18). 
Because of the high mobility of VM1 cells, it was difficult to identify individual 
colonies in these cells. Results showed that in clonogenicity assays, colony 
formation was not significantly influenced by FGF5 in the VM21 cell line. According 
to photometric measurement of the crystal violet absorption, there is an increased 
clonogenicity in VM1 cells with FGF5 over-expression compared to GFP control 
cells. 
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Figure 18: Photometric measurement of the crystal violet absorption in VM1 and VM21 cell lines showing a 
difference in clonogenicity of VM1 with over-expressed FGF5 compared to GFP.*p < 0.05  No difference was 
observed in colony formation of VM21 cells.                    
4.3.4 Soft agar assay 
VM1 and VM21 cell lines were tested for their anchorage independent growth in 
three dimensional cultures.  Cells were seeded in 10% RPMI medium including agar. 
Colony formation was monitored and the number of clones with a diameter above a 
specific threshold (> 20 μm VM21, > 15 μm VM1) was calculated. Cells were 
incubated about one month (Figure 19, 20). 
 
VM1- GFP                                                         VM1- FGF5 
                                         
VM 21- GFP                                             VM 21-FGF5 
 
Figure 19: VM1 and VM21 cells with over-expressed FGF5 were plated in soft agar at a density of 10000 
per 6-well. Clones formed under anchorage-independent conditions were evaluated after approx. 4 weeks  
of incubation. 
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Results showed no significant impact on the ability of cells expressing FGF5 to form 
clones in soft agar in contrast to cells with the GFP construct. 
 
 
 
 
 
 
 
        
 
 
 
 
 
 
                                       
 
Figure 20: Results of soft agar assays. VM1 and VM21cell lines were tested.10 000 cells were seeded. Four 
different areas per well were counted. 
4.3.5 Scratch assay 
The scratch assay (wound healing assay), is an in vitro method to investigate the 
migratory ability of cells. In a monolayer of cells a scratch "wound", is made with a 
pipette tip, so that a cell-free gap forms. The adjacent cells can moved into this 
vacant space. This is achieved through active cell movement. With this assay, the 
migration ability of VM1 and VM21 cells was tested after 4, 8, 24 and 48 h.  
Photographs after 4h are not shown (Figure 21, 22, 23, 24).  
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Figure 21: Example of a scratch assay of the VM1 cell line with over-expressed FGF5, after 8, 24 and 48h 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
Figure 22: Results of relative Migration of VM1 cells expressing FGF5 after   4, 8, 24, 48h. GFP cells were taken 
as a control. 
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Figure 23: Scratch assay of the VM21 cell line over-expressing FGF5 after 8, 24 and 48 h. Cells did not migrate 
properly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   
Figure 24: Result of migration of VM21 cells expressing FGF5 after 4, 8, 24, 48 h. VM21-GFP cells were 
 taken as a control. 
 
Results clearly show that FGF5 over-expression in VM1 cells has an impact on 
migration of cells. On the other hand in VM21 cells FGF5 up- regulation showed less 
stimulatory effects on migration.  
4.3.6 Invasion assay 
As described in the methods section, invasive cells are able to break down collagen 
and thus migrate through the pores of the membrane to the lower chamber. For this 
experiment just the cells with higher migration ability (VM1) were taken into 
consideration (Figure 25). The VM21 cell line was not further investigated, because 
cells did not migrate properly. 
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Figure 25: Invasion ability was tested with collagen-coated transwell chambers for the VM1 cell line. Cells were 
allowed to migrate to the lower chamber for 72 hours. Experiments were done in duplicates. Cells that migrated 
through the membrane and dropped to the bottom of the well were stained by crystal violet afterwards. 
 
Based on these results, over-expression of FGF5 stimulated cell migration through a 
collagen matrix (Figure 26).    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26 : Photometric measurement of the crystal violet absorption in VM1 cells with FGF5 over-expression 
that had formed colonies in the lower chamber of the transwell assay. Colony formation was strongly increased 
for VM1 cells with FGF5 in contrast to GFP control cells. ***p value < 0.001 
4.4 HET-CAM assay (ex vivo) 
To determine the contribution of FGF5 to melanoma cell-induced angiogenesis, the 
different over-expressing cell models were used in a hen´s egg chorioallantoic 
membrane assay. Recruitment of blood vessels by the growing tumor cells was 
monitored between embryonic days 7 and 11 and subsequently CAMs were 
processed for histology to screen for vessel growth and potential tumor cell invasion 
(Figure 27). The VM21 cell line with over-expressed FGF5 and the respective GFP 
control cell line were used for this assay. Figure 27 shows an example, where 
increased recruitment of blood vessels by VM21-FGF5 cells can be observed. 
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Figure 27:  A) Micrograph showing VM21-FGF5 cells on top of a hen´s egg CAM on embryonic  
day 8 as well as blood vessel recruitment by the tumor cells. In contrast, control cells transfected 
 with the GFP construct, (B) recruit fewer blood vessels.    
               
4.4.1 Immunohistochemical staining of hen´s egg CAM 
HE staining showed that the tumor is placed on top of the hen´s egg CAM. Staining 
of hen´s egg CAM with Ki-67 showed proliferation of growing tumor cells on the 
hen´s egg CAM (Figure 28).  
 
 
 
 
 
 
    
 
            
Figure 28: Histological and immunohistochemical demonstration of VM21 tumor cell growth on 
 a hen´s egg CAM. A) HE staining,  B) Ki-67 cell proliferation staining. 
 
Staining of hen´s egg CAM with anti-vWF antibodies showed clearly the endothelial 
cells (Figure 29). 
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Figure 29: A hen´s egg CAM was stained using anti-vWF antibody for demonstration of the FGF5 contribution in 
recruitment of blood vessels. 
 
4.5 In vivo tumor growth 
To investigate the impact of FGF5 on tumor growth in vivo, VM21-FGF5 and VM21 
control cells were injected subcutaneously into severe combined immunodeficient 
(SCID) mice and tumor growth was recorded. Compared to the mock transfected 
controls VM21-FGF5 cells formed palpable tumors earlier and tumor volume was 
increased (Figure 30). 
 
                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30 : VM21-FGF5 or VM21-Control cells were subcutaneously injected into the flanks of SCID mice (10
6
 
cells per mouse, 4 mice per group) and tumor growth was recorded over 40 days. Tumor volume was calculated 
as smaller diameter
2
 x larger diameter x 0.5. 
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According to the results shown in figure 19, tumor volume in VM21- FGF5 Cells was 
increased in contrast to mock transfected controls. This was also obvious, when the 
tumors were dissected out after sacrificing the mice (Figure 31). 
 
 
 
 
 
 
 
 
 
 
 
 
 
     Figure 31: Examples of the impact of FGF5 on tumour growth. A) Xenograft tumor from a mouse  
             with VM21-FGF5,  B) tumor from a control mouse engrafted with VM21-GFP cells. 
 
 
4.5.1 Immunohistochemical staining of VM21 xenograft tumors  
 
HE Staining 
This staining gives an overview of the structure of the tissue. Tumor cell necrosis 
was observed in the central part of the tumor (Figure 32). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 32 : Examples of histological sections of tumors xenografted VM21 cells A) the nuclei stain blue, dark 
violet to black. Cytoplasm, collagen, keratin and erythrocytes stain red. B) Histological specimen of tumor 
stained with HE shows necrosis in some parts of the tumor. 
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Ki-67 staining 
The Ki-67 protein is a cellular marker for proliferation. It is strictly associated with cell 
proliferation during late G1, S, G2 and M stages of cell cycle. Ki-67 staining of the 
xenografted tumors demonstarated a high rate of cell proliferation especially at the 
tumor margins (Figure 33). 
  
                                                               
 
 
 
 
 
 
                 
Figure 33 : A and B, Ki-67 cell proliferation staining of a tumor from VM21-FGF5 cells. 
  
von Willebrand Factor (vWF) Antibody Staining 
 
Endothelial cells were identified by staining for von Willebrand factor (vWF)  
(Figure 34). 
 
 
          
 
 
 
 
 
 
 
                                                                                                                                                                                
Figure 34: A and B von Willebrand factor (vWF) staining in a mouse engrafted with VM21- FGF5 cells 
  
4.6 HE staining of organs from mice engrafted with VM21-FGF5 or VM21-GFP 
Organs (lung, liver) from the xenotransplanted mice were formalin-fixed and stained 
with HE and Ki-67 in order to detect potential metastases derived from the 
xenografted tumors. However, staining of lung and liver indicated no metastatic cells 
in these organs (Figure 35). 
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Figure 35 : HE staining of A) Liver B) Lung of mice bearing VM21-FGF5 tumors. Nuclei are stained  
blue, the cytoplasm and extracellular
 
matrix have varying degrees of pink staining. 
 
 
4.7 Lentiviral shRNA-mediated knockdown of endogenous FGF5 
To investigate the effects of down regulated FGF5 expression, melanoma cells with 
high endogenous FGF5 expression (VM8, VM7 and VM47) were transduced with 
shRNA against FGF5. Five different hairpins were tested and a scrambled hairpin 
with no known cellular target was used as control. Puromycin resistance was used 
as selection marker. The knockdown of the endogenous FGF5 mRNA level was 
analyzed via qRT-PCR, using beta 2 microglobulin as house-keeping gene      
(Figure 36). 
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Figure 36: The knockdown of the endogenous FGF5 mRNA level was analyzed by qRT-PCR in melanoma cell 
lines (VM7, VM8, and VM47). 
 
Based on the data from the real-time PCR, the VM8 cell line transfected with the 
(TRCN0000058879 sh RNA) hairpin was chosen for further analysis. In VM7 (GTBS) 
cells no sufficient silencing of FGF5 could be achieved and VM47 (HOST) cells did 
not grow robustly enough under puromycin selection to allow further experiments.   
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4.8 Impact of down-modulation of endogenous FGF5 in vitro  
4.8.1 Effect of shRNA-mediated FGF5 down modulation on proliferation and viability 
of cells. 
To analyze the effect of FGF5 on cell proliferation and viability, VM8 cells were 
seeded and proliferation of cells was determined in a growth curve experiment. 
In comparison to the scrambled control, knockdown of endogenous FGF5 affected 
cell proliferation and reduced proliferation of cells after five days (Figure 37). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37: Proliferation of the VM8 cell line with FGF5 down-regulation determined by the Casy cell counter. 
Cells transfected with a scrambled shRNA were taken as control. 
 
To determine whether FGF5 knock-down has any effect on cell viability, VM8 cells 
were seeded in RPMI medium with 0.1% FBS and 10% FBS and cell viability was 
assessed by MTT assay after 5 days. Viability analyses by MTT showed no 
significant impact of FGF5 silencing on viability of cells in comparison to cells 
transfected with scrambled shRNA (Figure 38). 
 
 
 
 
 
 
 
                                        
 
 
VM8
0 2 4 6 8 10
0.0
2.0×1008
4.0×1008
6.0×1008
8.0×1008
1.0×1009
Scrambled
shFGF5
 F
o
ld
 G
ro
w
th
Days
55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38: viability of VM8 cell line with FGF5 down regulation incubated in RPMI medium with 0.1 and 10% FBS 
concentration for 5 days. 
 
4.8.2 Effect of siRNA-mediated FGF5 down-modulation on clonogenicity 
5000 VM8 cells were plated in 6-well plates for clonogenicity assays. After approx. 8 
days, colonies formed were fixed and stained. The colony formation was reduced for 
VM8 cells transduced with shFGF5 in comparison to the scrambled shRNA control 
(Figure 39). 
                                      sh Scr                            shFGF5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                             
Figure 39 : Effect of shRNA-mediated knockdown of endogenous FGF5 on colony formation. VM8 cells were 
seeded at low densities (5000 cells/well). Colony formation was determined after about 8 days. Two independent 
experiments were performed. 
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Figure 40: Results of crystal violet absorption showed a reduction in clonogenicity in VM 8 cells transfected with 
FGF5 shRNA compared to scrambled shRNA- transfected cells. ***p < 0.001. 
 
4.8.3 Effect of shRNA-mediated FGF5 down-modulation on invasion of cells 
To test the effect of FGF5 down-modulation on invasion and migration of cells, 
40000 VM8 cells with silenced FGF5 were seeded and incubate for 72 h. Only those 
cells able to migrate through the collagen coated membrane and settle on the 
bottom of the well were incubated for further 3 days. The colonies of these cells were 
fixed and stained by crystal violet afterwards (Figure 41). The results showed that 
colonies of FGF5 down regulated VM8 cells are fewer but have a larger size in 
contrast to control cells. Based on measurement of crystal violet absorption, more 
FGF5 knock down cells than control cells are present in the wells at the end of the 
experiment (Figure 42). 
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 sh Scr                      sh FGF5 
 
 
 
Figure 41: Invasion ability of VM8 cells with down-regulated FGF5 was tested. 40000 cells/well were seeded into 
collagen matrix-coated transwell chambers and incubated for 72 hours. Cells in the lower chamber were stained 
by crystal violet afterwards. At least two independent experiments in duplicates were performed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42: Results of photometric measurement of the crystal violet absorption of VM8 cells with silenced FGF5 
and control cells after migration through a collagen matrix. 
 
 
 
 
 
 
 
 
 
 
sh
 S
cr
 s
h 
FG
F5
0.00
0.05
0.10
0.15
58 
 
4.9 Treatment of melanoma cells with Neurolena lobata extract 
The aim of this part of the study was to test the inhibition effect of a plant extract 
from N. lobata on melanoma cell lines. N. lobata belongs to the family Asteraceae. 
Asteracea is the largest family of flowering plants and spread worldwide. It is divided 
into 11 subfamilies of which the subfamily Asteroideae comprises approximately 70 
% of specific diversity of the whole family. Since 2004, this subfamily is divided into 
three supertribes [91] of which Helianthodae comprises the species N.lobata. This 
plant is spread in Latin American countries and can be found especially in 
Guatemala and Costa Rica. It has been suggested that N. lobata extract has an 
inhibition effect on the expression of receptor tyrosine kinases at the transcription 
level. For this purpose five melanoma cell lines (VM1, VM21, VM24 and VM48) were 
seeded in 96-well plates and incubated overnight. Next day the cells were treated 
with different concentration of N. lobata extract and incubated for 5 days. After that 
viability of the cells was measured by MTT assay (Figure 43). 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43 : MTT assay of the four melanoma cell lines VM1, VM21, VM24 and VM48. 3000cells per well  
were treated with N. lobata extract and incubated for 5 days. 
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Results showed that N.lobata extract has a concentration-dependent toxic effect in 
all four tested melanoma cell lines. 
4.9.1 Effect of N. lobata on FGF/FGFR expression  
Since N. lobata extract was suggested to influence the transcription of specific 
genes, it was tested, whether treatment with N.lobata extract has an impact on the 
expression of FGFR1, FGFR4 or FGF2 in melanoma cells. VM21 cells were treated 
with 5 µg/ml N. lobata extract for 24 h. qRT-PCR of FGFR1, FGFR4 and FGF2 was 
performed in these cells (Figure 44). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44: Quantitative expression analysis (qRT-PCR) of FGFR1, 4 and FGF2 in the VM21 cell line after 
treatment with 5 µg/ml N. lobata extract (NL). The DMSO control (Co) was taken as reference.  
Beta-2 microglobulin was used as house-keeping gene. 
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Expression analysis by qRT-PCR revealed no significant difference in expression of 
FGFR1 and 4 in cells after treatment with N. lobata extract compared to DMSO 
treated control cells, whereas a reduction of FGF2 expression was observed in cells 
with N. lobata treatment in contrast to DMSO-treated cells. 
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5 Discussion 
The fibroblast growth factor (FGF) signaling system is involved in normal cell growth 
survival, differentiation, and angiogenesis. Thus, deregulated FGF/FGFR-mediated 
signalling has been implicated in carcinogenesis. Over-expression of growth and 
survival promoting factors is an important hallmark of neoplastic cells and a major 
driving force for tumor progression and dissemination. Over-expression of FGF 
ligands has been identified in a great variety of human tumors. 
There are some  possibilities how to release FGF: first, FGFs may be overexpressed 
and secreted by the tumor cells themselves; for example FGF2 mRNA has been 
shown to be expressed in over 94% of human gliomas [83] however, the FGF-2 
protein has not been detected in normal brain by immunohistochemistry [80]. The 
expression of FGF-2 has also been shown positively to correlate with the degree of 
malignancy and vascularity in human gliomas [80].  
Secondly, FGFs may be secreted by the stromal cells in response to a signal from 
the tumor cells; an example for this possibility is illustrated with FGF5 in pancreatic 
cancer. FGF3, 4 and 8 which are normally not expressed to high levels in adult 
tissues have been found in a number of human neoplasms, for instance in Kaposi´s 
sarcoma, and in carcinomas of the breast, prostate, ovary and esophagus [81-84]. 
Expression of FGF2 has been identified as important characteristic of melanoma 
cells in contrast to normal melanocytes [85] and has been linked to tumor 
progression in melanoma and multiple other malignancies [86].  
An autocrine growth stimulatory role for FGF2 in melanoma has been clearly shown 
through inhibition of FGF2 activity by intracellular injection of blocking antibodies 
[84, 74]. Expression analysis showed that FGFR1 and FGFR4 are highly expressed 
in nearly all melanoma cell lines, compared to FGFR2 and FGFR3.Recent studies in 
melanoma  revealed that tumor growth or cell proliferation is reduced to about 50%, 
when infected with adenoviruses bearing dnFGFR1 constructs, compared to GFP as 
control [75]. In a previous study, very low expression of FGF5 in melanocytes and 
90% over-expression of FGF5 in the majority of the tested melanoma cell lines was 
found [28]. 
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5.1 Impact of FGF5 on the malignant phenotype in vitro 
In the present study, two melanoma cell lines (VM1, VM21) with low endogenous 
FGF5 expression were stably transfected with a vector containing human FGF5, 
GFP and an IRES-binding site from a bicistronic mRNA as well as a G418 resistance 
marker and the impact of FGF5 over-expression on the malignant phenotype of 
melanoma was characterized in these cell lines by subjecting them to different in 
vitro assays. 
Results of the scratch assay clearly showed the influence of FGF5 over-expression 
to result in a more migratory phenotype in the VM1 cell line, in agreement with a 
recent study, demonstrating that FGF5 stimulates migration of glioblastoma cell lines 
[44]. On the other hand in VM21 cells FGF5 up-regulation showed less stimulatory 
effects on migration in the scratch assay. In invasion assays only the cells with 
higher migration ability (VM1) were taken into consideration and the impact of FGF5 
on migration ability of cells through a collagen matrix was demonstrated. 
An increased clonogenicity was observed in VM1 cells with FGF5 over-expression 
compared to GFP control. Again, in the VM21 cell line colony formation was not 
significantly influenced by FGF5. No significant impact on the ability of cells 
expressing FGF5 to form clones was observed in soft agar in contrast to cells with 
the GFP construct. The MTT assay showed a decrease in viability of cells with FGF5 
over-expression in RPMI medium with 0.1% FBS. A slight increase in viability of 
VM1 in medium with 10% FBS was observed, whereas in VM21 cells no difference 
was detected. The decreased viability of cells with FGF5 over-expression in medium 
with low serum was unexpected and the reason is not clear.   
Relating to effects of FGF5 over-expression on proliferation of VM1 and VM21 cells, 
no difference was observed in contrast to GFP over-expressing cells. Thus, FGF5 
over-expression did not stimulate melanoma cell proliferation in vitro. 
5.2 Hen´s egg chorioallantoic membrane (HET-CAM) 
The purpose of this assay was to determine the contribution of FGF5 to melanoma 
cell-induced angiogenesis. Results show the recruitment of blood vessels by the 
growing tumor cells (VM21 cells with FGF5 over-expression) on top of a hen´s egg 
CAM. FGF5 may exert paracrine effects on vascular endothelial cells that are 
mediated through FGFRs 1 and 2 , the main FGFRs on endothelial cells [28]. 
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FGF5 was recently recognized as a potent inducer of tube formation of endothelial 
cells [43]. It was also demonstrated that tumor cell-derived FGF5 induces 
differentiation in human umbilical cord endothelial cells in vitro with an activity similar 
to vascular endothelial growth factor (VEGF) and stimulates the growth of vascular 
endothelial cells [49]. VEGF and basic fibroblast growth factor (bFGF, FGF2) are 
recognized as stimulators of migration and angiogenesis during the progression of 
melanoma [88]. The present study may confirm the role of FGF5 as an important 
player in melanoma cell-induced angiogenesis. The quantification of the HET-CAM 
data, however, is challenging and the method still needs to be improved to allow a 
statistical comparison between FGF5 over-expressing and GFP over-expressing 
melanoma cells. 
5.3 Lentiviral shRNA-mediated knockdown of endogenous FGF5 
In our study, silencing of FGF5 with lentiviral siRNA in VM8 cells, which have a high 
level of endogenous FGF5, reduced cell proliferation after five days in contrast to 
cells with control shRNA. While, as mentioned above, FGF5 over-expression did not 
induce an increase in cell proliferation in vitro. Results are in agreement with data 
from the literature showing that siRNA-mediated FGF5 down-modulation reduced 
glioblastoma cell proliferation [43]. Viability analyses by MTT assay, however, 
showed no significant impact of FGF5 silencing on viability of cells in comparison to 
cells transfected with scrambled shRNA. In clonogenicity assays, the formation of 
colonies was reduced for VM8 cells when FGF5 was silenced by shRNA. It is 
presumed that the down modulation of FGF5 reduced clone formation in the 
clonogenic assay. Relating to migration ability of cells with shRNA-mediated FGF5 
silencing, measurement of crystal violet absorption shows no significant effect of 
FGF5 down-regulation on invasion ability of cells in contrast to cells expressing 
scrambled shRNA. 
Taking these results together, shRNA-mediated knockdown of endogenous FGF5 
appears to have an inhibitory effect on cell proliferation and colony formation in vitro. 
5.4 In vivo tumor growth 
The impact of FGF5 on tumor growth in vivo was tested by a xenotransplantation 
experiment in SCID mice. VM21 melanoma cells with FGF5 over-expression and 
respective control cells were injected subcutaneously into the flanks of SCID mice. 
The results clearly show that VM21-FGF5 formed palpable tumors earlier and tumor 
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volume was increased in contrast to mock transfected controls. This result supports 
the hypothesis that FGF5 over-expression contributes to the malignant phenotype of 
melanoma cells and results in more aggressive tumor growth. This is the first study 
to demonstrate increased tumor growth as a result of FGF5 over-expression in vivo. 
In other studies it has been shown that FGF8b-transfected MCF-7 human breast 
cancer cells formed faster growing tumors than vector-only-transfected cells when 
xenografted into nude mice [86].  
HE staining of tumors showed tumor cell necrosis in the central part of the tumor. 
Results of Ki-67 staining demonstarated a high rate of cell proliferation especially at 
the tumor margins.Endothelial cells were identified by staining for von Willebrand 
factor (VWF) in tumors. Identification of endothelial cells in tumors correlated with 
the finding that tumor angiogenesis activates endothelial cell proliferation, recruits 
migrating endothelial cells and pericytes, and forms new blood vessels through 
vascular remodeling and maturation [89]. In HE and Ki-67 stainings of lungs and 
livers of xenotransplanted mice no incidence of potential metastases derived from 
the xenografted tumors was observed. 
5.5 Treatment of melanoma cells with Neurolena lobata extract 
Results of MTT assay showed that N. lobata extract has a concentration-dependent 
cytotoxic effect in all four tested melanoma cell lines. Although only few studies are 
available on cytotoxicity of N. lobata, our data are consistent with the studies, which 
revealed that lobatin B of N. lobata was the compound with the strongest cytotoxic 
activity in GLC4 and COLO 320 tumor cell lines [90]. Recently N. lobata extract was 
shown to inhibit expression of the NPM/ALK fusion oncogene present in a high 
fraction of anaplastic large cell lymphomas (ALCL) [91]. Whether the observed 
reduction of FGF2 expression in VM21 cells contributes to the cytotoxicity of N. 
lobata extract in melanoma cells remains to be determined. Expression analysis 
showed no significant difference in expression of FGFR1and 4 after treatment with 
N. Lobata. 
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6.3 Abbreviations 
EtOH – Ethanol 
FGF - Fibroblast Growth Factor 
FGFR - Fibroblast Growth Factor Receptors 
FGF-BP - FGF Binding Protein 
FRS2 - Fibroblast Growth Factor Receptor Substrate 2 
IRES - Internal Ribosomal Entry Site 
MAPK - Mitogen Activated Protein Kinase 
ERK - Extracellular Signalregulated Kinase 
PAGE - Polyacrylamide Gelelectrophoresis 
PBS - Phophate Buffered Saline 
ROS - Reactive Oxygen Species 
RPMI - Roswell Park Memorial Institute 
RT - Room Temperature 
SCID - Severe Combined Immunodeficiency 
SDS - Sodium Dodecyl Sulfate 
TBS - Tris Buffered Saline 
TEMED - N,N,N´,N´-Tetramethylethylenediamine 
Tris - Trishydroxymethyl Aminomethane 
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